Alcoholism
AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
Published in Oncology Business Week, July 26th, 2009
AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, announced publication in the renowned American scientific journal, Proceedings of the National Academy of Sciences (PNAS), of new data supporting the use of AEterna Zentaris' ghrelin receptor antagonist compound, AEZS-123 (JMV2959), for the treatment of alcohol dependence that involves ghrelin. Ghrelin is a hormone produced by the stomach and acting in the brain. Compelling evidence obtained with the administration of AEZS-123, and a ghrelin receptor mouse knockout model, highlights the role of ghrelin to regulate the rewarding value of alcohol in a mouse model of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
More Articles from Oncology Business Week
- 1720 Entertainment
1720 Entertainment and Possibility Pictures Form Strategic Partnership - Abbott
Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal Vet, a New Chemotherapeutic Agent for Dogs - Aeolus Pharmaceuticals, Inc.
Aeolus Pharmaceuticals' AEOL 10150 Significantly Increases Survival in Mice Exposed to Radiation when Administered After Exposure - Allos Therapeutics, Inc.
Allos Therapeutics Completes Enrollment in Randomized Phase 2b Trial of Pralatrexate in Patients with Advanced Non-Small Cell Lung Cancer - Alzheimer Disease
Perceptive Informatics Enhances CNS and Oncology Medical Image Processing and Analysis Capabilities Through Alliance With Biospective - Array BioPharma Inc.
Array BioPharma Announces Top-Line Results in Two Phase 1 Clinical Trials - More from this issue of Oncology Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
